• Financial performance: Morepen reported 34% revenue growth to nearly INR 575 crore and an EBITDA increase exceeding 200%, supported by operating leverage, improved API pricing, and EBITDA margins crossing 15%.
• CDMO order execution: Early shipments began in Q1 against an INR 823–825 crore CDMO order, which is scheduled to be completed over the next four to five quarters while management works to diversify the customer base.
• Revenue mix targets: CDMO revenue is expected to surpass 50% of total revenue by Q3–Q4, rise to 60% in the medium term, and potentially reach up to 75% within another year.
• Regulatory track record: The company cites key competitive strengths including zero Form 483 observations across its last four USFDA inspections, no import alerts over 25 years, and large ready-made manufacturing capacities.
• Product roadmap expansion: Morepen is transitioning toward higher-margin, innovation-led manufacturing by setting up a pilot plant for high-potency APIs and planning long-term capability expansion into peptides and oligonucleotides.